168 related articles for article (PubMed ID: 38659649)
21. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
22. HDAC9 deficiency promotes tumor progression by decreasing the CD8
Ning Y; Ding J; Sun X; Xie Y; Su M; Ma C; Pan J; Chen J; Jiang H; Qi C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554611
[TBL] [Abstract][Full Text] [Related]
23. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
24. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8
Hermans D; Gautam S; García-Cañaveras JC; Gromer D; Mitra S; Spolski R; Li P; Christensen S; Nguyen R; Lin JX; Oh J; Du N; Veenbergen S; Fioravanti J; Ebina-Shibuya R; Bleck C; Neckers LM; Rabinowitz JD; Gattinoni L; Leonard WJ
Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6047-6055. PubMed ID: 32123114
[TBL] [Abstract][Full Text] [Related]
25. Combinatorial immunotherapy induces tumor-infiltrating CD8
Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555
[TBL] [Abstract][Full Text] [Related]
26. Deleting the mitochondrial respiration negative regulator MCJ enhances the efficacy of CD8
Wu MH; Valenca-Pereira F; Cendali F; Giddings EL; Pham-Danis C; Yarnell MC; Novak AJ; Brunetti TM; Thompson SB; Henao-Mejia J; Flavell RA; D'Alessandro A; Kohler ME; Rincon M
Nat Commun; 2024 May; 15(1):4444. PubMed ID: 38789421
[TBL] [Abstract][Full Text] [Related]
27. JAML promotes CD8 and γδ T cell antitumor immunity and is a novel target for cancer immunotherapy.
McGraw JM; Thelen F; Hampton EN; Bruno NE; Young TS; Havran WL; Witherden DA
J Exp Med; 2021 Oct; 218(10):. PubMed ID: 34427588
[TBL] [Abstract][Full Text] [Related]
28. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
29. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance.
Palmer DC; Guittard GC; Franco Z; Crompton JG; Eil RL; Patel SJ; Ji Y; Van Panhuys N; Klebanoff CA; Sukumar M; Clever D; Chichura A; Roychoudhuri R; Varma R; Wang E; Gattinoni L; Marincola FM; Balagopalan L; Samelson LE; Restifo NP
J Exp Med; 2015 Nov; 212(12):2095-113. PubMed ID: 26527801
[TBL] [Abstract][Full Text] [Related]
30. Sepsis-Induced State of Immunoparalysis Is Defined by Diminished CD8 T Cell-Mediated Antitumor Immunity.
Danahy DB; Kurup SP; Winborn CS; Jensen IJ; Harty JT; Griffith TS; Badovinac VP
J Immunol; 2019 Aug; 203(3):725-735. PubMed ID: 31189573
[TBL] [Abstract][Full Text] [Related]
31. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
Ribas A; Wargo JA; Comin-Anduix B; Sanetti S; Schumacher LY; McLean C; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS
J Immunol; 2004 Apr; 172(8):4762-9. PubMed ID: 15067052
[TBL] [Abstract][Full Text] [Related]
32. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
Zhang X; Niedermann G
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
[TBL] [Abstract][Full Text] [Related]
33. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
[TBL] [Abstract][Full Text] [Related]
34. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.
Xie Y; Wang L; Freywald A; Qureshi M; Chen Y; Xiang J
Cell Mol Immunol; 2013 Jan; 10(1):72-7. PubMed ID: 23042534
[TBL] [Abstract][Full Text] [Related]
35. Anti-VEGF Treatment Enhances CD8
de Almeida PE; Mak J; Hernandez G; Jesudason R; Herault A; Javinal V; Borneo J; Kim JM; Walsh KB
Cancer Immunol Res; 2020 Jun; 8(6):806-818. PubMed ID: 32238381
[TBL] [Abstract][Full Text] [Related]
36. IL-36β Promotes CD8
Zhao X; Chen X; Shen X; Tang P; Chen C; Zhu Q; Li M; Xia R; Yang X; Feng C; Zhu X; Zhu Y; Sun Z; Zhang X; Lu B; Wang X
Front Immunol; 2019; 10():1803. PubMed ID: 31447838
[TBL] [Abstract][Full Text] [Related]
37. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
38. IL7-Fc Enhances the Efficacy of Adoptive T Cell Therapy under Lymphopenic Conditions in a Murine Melanoma Model.
Yu EM; Cho E; Singh R; Kim SH; Han C; Han S; Lee DG; Kim YH; Kwon BS; Choi BK
Cells; 2021 Aug; 10(8):. PubMed ID: 34440787
[TBL] [Abstract][Full Text] [Related]
39. Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer.
Celus W; Oliveira AI; Rivis S; Van Acker HH; Landeloos E; Serneels J; Cafarello ST; Van Herck Y; Mastrantonio R; Köhler A; Garg AD; Flamand V; Tamagnone L; Marine JC; Di Matteo M; Costa BM; Bechter O; Mazzone M
Cancer Immunol Res; 2022 Jan; 10(1):126-141. PubMed ID: 34815265
[TBL] [Abstract][Full Text] [Related]
40. Subsets of exhausted CD8
Miller BC; Sen DR; Al Abosy R; Bi K; Virkud YV; LaFleur MW; Yates KB; Lako A; Felt K; Naik GS; Manos M; Gjini E; Kuchroo JR; Ishizuka JJ; Collier JL; Griffin GK; Maleri S; Comstock DE; Weiss SA; Brown FD; Panda A; Zimmer MD; Manguso RT; Hodi FS; Rodig SJ; Sharpe AH; Haining WN
Nat Immunol; 2019 Mar; 20(3):326-336. PubMed ID: 30778252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
